AndhraNews.net
Home » Features » Health » Foetus

Foetus


About Foetus

A fetus (also spelled foetus, fœtus, faetus) is a developing mammal or other viviparous vertebrate after the embryonic stage and before birth.

Foetus in News

Oral REVLIMID® Plus Dexamethasone Granted Approval for Treatment of Patients with Newly Diagnosed Multiple Myeloma in Japan
Business Wire India

Takeda Presents Data from Phase 3 TOURMALINE-MM1 Study for NINLARO® (ixazomib), First and Only Once-Weekly Oral Proteasome Inhibitor Recently Approved for Multiple Myeloma
Business Wire India

U.S. FDA Approves Takeda’s NINLARO® (ixazomib), the First and Only Oral Proteasome Inhibitor to Treat Multiple Myeloma
Business Wire IndiaTakeda Pharmaceutical Company Limited (TSE: 4502) today announced that the U.S

Pfizer Reports Positive Topline Results from Phase 3 Trial Comparing XALKORI® (crizotinib) to Chemotherapy in Previously Untreated East Asian Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)
Business Wire IndiaPfizer Inc

Takeda to Present Data from Ixazomib’s Phase 3 Study in Relapsed/Refractory Multiple Myeloma at Upcoming American Society of Hematology Annual Meeting
Business Wire IndiaTakeda Pharmaceutical Company Limited (TSE: 4502) announced that it will present Phase 3 data from the TOURMALINE-MM1 ixazomib clinical trial at the 57th American Society of Hematology (ASH) Annual Meeting to be held in Orlando, Florida from December 5 to 8, 2015

Seattle Genetics and Takeda Achieve Target Enrollment in Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (Brentuximab Vedotin) in Previously Untreated Advanced Hodgkin Lymphoma (HL)
Business Wire IndiaSeattle Genetics, Inc. (Nasdaq: SGEN) and Takeda Pharmaceutical Company Limited (TSE:4502) today announced that the companies have achieved completion of target patient enrollment in the phase 3 ECHELON-1 clinical trial

One Year Data from Phase III Study Evaluating Oral OTEZLA® (apremilast) or Injectable etanercept versus Placebo in Patients with Moderate to Severe Plaque Psoriasis Presented at EADV
Business Wire India

Celgene Announces New Data for OTEZLA® (Apremilast) Will Be Presented at European Academy of Dermatology and Venereology Congress
Business Wire India

Pampers and UNICEF Celebrate a Decade Together Helping to Save Millions of Mother’s and Babies’ Lives
Business Wire IndiaAn estimated 500,000 newborn lives have been saved and 100 million women and their newborns protected from the deadly disease, maternal and newborn tetanus, thanks to a ten-year long partnership between Pampers® and UNICEF that helped achieve this milestone.

Celgene’s VIDAZA® (Azacitidine for Injection) Receives Positive CHMP Opinion as New Treatment for Elderly Patients with Acute Myeloid Leukaemia
Business Wire India

Therapeutic Solutions International Announces the Licensing of Probiotic Technology to OmniBiome, Inc.
Therapeutic Solutions International, Inc. (OTC PINK: TSOI) announced today that the Company has licensed an additional Patent to OmniBiome, Inc. (Omni), a wholly owned subsidiary of Therapeutic Solutions International, Inc., focused on Fetal-Maternal Health.

Navamedic to launch non-invasive prenatal tests in Nordic markets
Navamedic ASA (OSE: NAVA), the Norwegian medtech and pharmaceutical products company, announced today an agreement signed with Sequenom Laboratories of USA, a leading molecular diagnostics laboratory, for the launch of three non-invasive prenatal genetic tests in the Nordic region.

VIVUS Reports Third Quarter 2015 Financial Results
MOUNTAIN VIEW, CA--(Marketwired - November 04, 2015) - VIVUS, Inc. (NASDAQ: VVUS) (the "Company"), a biopharmaceutical company commercializing and developing innovative, next-generation therapies to address unmet needs in obesity and sexual health, today provided a business update and reported its financial results for the third quarter ended September 30, 2015.

VIVUS Announces Qsymia Presentations at Obesity Week 2015
MOUNTAIN VIEW, CA--(Marketwired - November 03, 2015) - VIVUS, Inc. (NASDAQ: VVUS) (the "Company"), a biopharmaceutical company commercializing Qsymia® (phentermine and topiramate extended-release) capsules CIV for the treatment of obesity, today announced the following presentations at Obesity Week 2015, Los Angeles Convention Center

Egg Phosphatidylcholine Market Is Expected to Reach $12.2 Million by 2020: Hexa Research
Egg phosphatidylcholine is used to improve liver functionality and enhance the functioning of digestive system in elderly people. Increasing old age population is expected to drive the market growth. Moreover, egg phosphatidylcholine is used as means of relief for food allergies which in turn is expected to drive demand in dietary supplements

Data From New Retrospective Studies of VIBATIV(R) (Telavancin) Demonstrate Positive Clinical Outcomes for Patients With Difficult-to-Treat, Gram-Positive Infections, Including MRSA
Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") today announced new positive data from multiple retrospective studies of VIBATIV® (telavancin) demonstrating positive clinical outcomes for patients with Staphylococcus aureus (S. aureus) bacteremia and methicillin-resistant S. aureus (MRSA) osteomyelitis following treatment with VIBATIV

Theravance Biopharma to Present New Retrospective Clinical Data on VIBATIV(R) (telavancin) Showing Positive Outcomes for Patients With Difficult-to-Treat Infections, Including MRSA, at IDWeek 2015
Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") today announced that data from studies of VIBATIV® (telavancin) will be presented at IDWeek™ 2015, being held in San Diego, CA, on October 7 - 11, 2015. New data from multiple retrospective clinical studies demonstrating positive outcomes for patients with Staphylococcus aureus (S

Data From New Studies Confirm In Vitro Potency of VIBATIV(R) (Telavancin) Against Gram-Positive Bacteria, Including MRSA
Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") today announced new positive data from several studies of VIBATIV® (telavancin) confirming the product's in vitro potency against isolates from a range of difficult-to-treat infections

Trade Press release: CAE Healthcare to host first bilingual HPSN Europe conference with Francisco de Vitoria University in Madrid
CAE Healthcare kicks off its tenth annual Human Patient Simulation Network (HSPN) Europe conference today in Madrid with a record number attendees and academic presentations in both Spanish and English

Theravance Biopharma Announces FDA Acceptance of sNDA to Expand VIBATIV(R) (telavancin) Labeling
Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company's supplemental New Drug Application (sNDA) for VIBATIV® (telavancin)

Celgene Receives Positive CHMP Opinion to Extend REVLIMID® (Lenalidomide) for Continuous Use in Patients with Newly Diagnosed Multiple Myeloma and Ineligible for Transplant

Seattle Genetics and Takeda Report Phase 3 AETHERA Clinical Trial Data from ADCETRIS® (Brentuximab Vedotin) in Post-Transplant Hodgkin Lymphoma Patients at Risk of Relapse at ASH Annual Meeting
Seattle Genetics, Inc

Seattle Genetics and Takeda Announce Four-Year Survival Data from ADCETRIS® (Brentuximab Vedotin) Pivotal Trial in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma at ASH Annual Meeting
Seattle Genetics, Inc. (Nasdaq: SGEN) and Takeda Pharmaceutical Company Limited (TSE:4502) has announced four-year overall survival (OS) data from the ADCETRIS (brentuximab vedotin) pivotal Phase 2 clinical trial in relapsed or refractory systemic anaplastic large cell lymphoma (ALCL)

Celgene Receives Positive CHMP Opinion for OTEZLA® (apremilast), the First Oral PDE4 Inhibitor for the Treatment of Patients with Psoriasis and Psoriatic Arthritis

Oral OTEZLA® (Apremilast) Showed Sustained Clinical Response over Two Years in Patients with Active Psoriatic Arthritis
Celgene Corporation (NASDAQ:CELG), today announced that results from long-term (104-week) efficacy and safety analyses of OTEZLA® (apremilast) from the open-label phase of two PALACE phase III clinical trials were presented at the 2014 American College of Rheumatology (ACR)/Association of Rheumatology Health Professionals (ARHP) annual meeting in Boston

Takeda Announces Abstracts for ADCETRIS® (brentuximab vedotin) in Hodgkin Lymphoma, Systemic Anaplastic Large Cell Lymphoma and Ixazomib in Multiple Myeloma to be Presented at 56th American Society of Hematology Annual Meeting

New Analyses of Oral OTEZLA® (Apremilast) Presented at EADV Show Efficacy in Difficult-to-Treat Areas of Moderate to Severe Plaque Psoriasis
Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:CELG), has announced that results from additional efficacy and safety analyses of OTEZLA® (apremilast) from the ESTEEM phase III clinical trial program were released at the 23rd European Academy of Dermatology and Venereology (EADV) Congress in Amsterdam

Oral OTEZLA® (apremilast) Data Presented at EADV Show Improved Measures of Health-Related Quality of Life and Work Productivity in Patients with Moderate to Severe Plaque Psoriasis
Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ: CELG) has announced that patient-reported health outcomes data for OTEZLA® (apremilast) were presented at the 23rd European Academy of Dermatology and Venereology (EADV) Congress in Amsterdam

Seattle Genetics and Takeda Announce Positive Data from Phase 3 AETHERA Clinical Trial of ADCETRIS® (Brentuximab Vedotin) for Consolidation in Post-Transplant Hodgkin Lymphoma
Seattle Genetics, Inc


TEMPE, AZ--(Marketwired - December 29, 2014) - New Top-10 listings from American Traffic Solutions (ATS), the nation's leading provider of road safety cameras, names the Honda Accord as the most frequent make and model of vehicle caught running red lights in 2014, and finds most red-light runners were driving vehicles painted gray.

VIVUS Announces Favorable Formulary Positioning for Qsymia
MOUNTAIN VIEW, CA--(Marketwired - December 15, 2014) - VIVUS, Inc. (NASDAQ: VVUS), a biopharmaceutical company commercializing Qsymia® (phentermine and topiramate extended-release) capsules CIV for the treatment of obesity, today announced that Qsymia is the sole anti-obesity agent listed on the CVS/Caremark Performance Drug List, or PDL

DNA Sequencing Breakthrough -- Ex-Groupon CEO Joins Prenetics, Launches Non-Invasive Prenatal Test in Hong Kong
Prenetics™, a DNA biotechnology company, announces Danny Yeung has joined the company as its CEO and investor, as well as having led a $2.65M USD strategic seed funding round of high profile international investors into the company. Danny most previously was CEO of Groupon East Asia after having his start-up uBuyiBuy acquired by Internet Giant Groupon in 2010

Theravance Biopharma, Inc. Reports Third Quarter 2014 Financial Results
Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company"), through its U.S. operating subsidiary, Theravance Biopharma US, Inc., today reported financial results for the third quarter 2014. Revenue for the third quarter of 2014 was $6.3 million. Net loss for the third quarter of 2014 was $54.5 million or $1.72 per share

VIVUS Reports Third Quarter 2014 Financial Results
MOUNTAIN VIEW, CA--(Marketwired - November 05, 2014) - VIVUS, Inc. (NASDAQ: VVUS), a biopharmaceutical company commercializing Qsymia® (phentermine and topiramate extended-release) capsules CIV for the treatment of obesity, today reported its financial results for the third quarter ended September 30, 2014 and provided a business update.

Breakthrough Diabetes Research to Be Commercialized by US-Based Nuvilex, Inc.
SYDNEY, AUSTRALIA--(Marketwired - November 03, 2014) - Australian research that has produced a line of insulin producing cells that could eliminate the need for injections for Type 1 diabetics will be commercialized by US company Nuvilex, Inc. (OTCQB: NVLX) and its subsidiaries Nuvilex Australia and Nuvilex Europe.

VIVUS Announces Qsymia Presentations at Obesity Week 2014

Reprogenetics Announces Strategic Collaboration for Next-Generation In-Vitro Fertilization Sequencing Systems
Reprogenetics, the largest U.S. genetics laboratory specializing in Preimplantation Genetic Screening (PGS) and Preimplantation Genetic Diagnosis (PGD), announced today that the company has signed a collaboration agreement with genomics leader Illumina as its preferred partner for the research and development of in-vitro fertilization (IVF)-related sequencing technologies

Newly Published Data Highlight the Effects of Weight Loss With Qsymia in Type 2 Diabetes
MOUNTAIN VIEW, CA--(Marketwired - October 06, 2014) - VIVUS, Inc. (NASDAQ: VVUS) today announced the publication of a paper examining study results that demonstrate the positive impact of weight loss with Qsymia® (phentermine and topiramate extended-release) capsules CIV (PHEN/TPM ER) plus lifestyle modification on glycemic control in subjects with type 2 diabetes.

Theravance Biopharma Provides VIBATIV(R) (telavancin) Product Update
Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") today provided a product update for VIBATIV® (telavancin), the Company's proprietary FDA-approved bactericidal, once-daily, injectable lipoglycopeptide antibiotic

VIVUS Announces Acquisition of Topiramate-Related Patents From Janssen Pharmaceuticals
MOUNTAIN VIEW, CA--(Marketwired - August 25, 2014) - VIVUS, Inc. (NASDAQ: VVUS) today announced the acquisition of a group of patents from Janssen Pharmaceuticals, Inc. covering uses of topiramate as monotherapy and in combination with other pharmaceutical agents to treat a variety of medical conditions.

Iroko Pharmaceuticals Enters into Strategic Agreements to Expand Commercialization of ZORVOLEXTM (diclofenac) Outside the U.S.
Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, today announced that its affiliate, Iroko Pharmaceuticals Inc

Seattle Genetics and Takeda Highlight Long-term Follow-up Data from ADCETRIS® (Brentuximab Vedotin) Pivotal Clinical Trials in Relapsed or Refractory Hodgkin Lymphoma and Systemic Anaplastic Large Cell Lymphoma at ASH 2013
Seattle Genetics, Inc

ABRAXANE® Phase III Study of Patients with Metastatic Pancreatic Cancer Published in New England Journal of Medicine

Natera Expands PanoramaTM to Include Detection of Triploidy, Following Publication of Validation Data in Fetal Diagnosis and Therapy
Natera, a leading innovator in prenatal genetic testing, today announced that, following publication of validation data in Fetal Diagnosis and Therapy, its non-invasive prenatal test Panorama™ is being expanded to offer detection of triploidy

Oral Anti-Cancer Therapy Pomalidomide Now Approved by European Commission as Treatment for Patients with Relapsed/Refractory Multiple Myeloma – a Rare Form of Blood Cancer

Celgene Will Discontinue Phase III ORIGIN® Trial in Previously Untreated Elderly Patients with B-Cell Chronic Lymphocytic Leukemia
Celgene Corporation (NASDAQ: CELG) today announced that after consultation with the U.S. Food and Drug Administration (FDA) Celgene will discontinue treatment with REVLIMID® (lenalidomide) in the open-label, phase III ORIGIN® trial, which enrolled 450 patients in over 100 sites in 26 countries

FDA Approves Epaned, a Liquid Form of Enalapril for Children and Adults
In the news release, "FDA Approves Epaned, a Liquid Form of Enalapril for Children and Adults," issued earlier today by Silvergate Pharmaceuticals, Inc., the correct contact phone number for information about Epaned is 1-855-379-0382. Please update your records accordingly. Complete corrected text follows.

Cornerstone Therapeutics Launches BETHKIS(R) (Tobramycin Inhalation Solution) for Management of Cystic Fibrosis Patients With Pseudomonas Aeruginosa
Cornerstone Therapeutics Inc. (NASDAQ: CRTX) announced today the launch of BETHKIS® (Tobramycin Inhalation Solution), a nebulized therapy indicated for the management of cystic fibrosis (CF) patients with Pseudomonas aeruginosa

Actelion launches VALCHLOR (mechlorethamine) gel 0.016% in the US
Actelion Pharmaceuticals Ltd /Actelion launches VALCHLOR (mechlorethamine) gel 0.016% in the US. Processed and transmitted by Thomson Reuters ONE.The issuer is solely responsible for the content of this announcement.

Actelion announces U.S. commercial availability of opsumit (macitentan) as of November 4
Actelion Pharmaceuticals Ltd /Actelion announces U.S. commercial availability of opsumit (macitentan) as of November 4 . Processed and transmitted by Thomson Reuters ONE.The issuer is solely responsible for the content of this announcement.

Further positive Opsumit (macitentan) data in pulmonary arterial hypertension presented at CHEST 2013
Actelion Pharmaceuticals Ltd /Further positive Opsumit (macitentan) data in pulmonary arterial hypertension presented at CHEST 2013 . Processed and transmitted by Thomson Reuters ONE.The issuer is solely responsible for the content of this announcement.

Theravance Reports Third Quarter 2013 Financial Results
Theravance, Inc. (NASDAQ: THRX) (the "Company") reported today its financial results for the quarter ended September 30, 2013. Revenue for the third quarter of 2013 was $0.4 million. Net loss for the third quarter of 2013 was $47.0 million or $0.44 per diluted share. Cash and cash equivalents, short-term investments and marketable securities totaled $594.5 million as of September 30, 2013.

Actelion receives US FDA approval of Opsumit (macitentan) for the treatment of pulmonary arterial hypertension
Actelion Pharmaceuticals Ltd /Actelion receives US FDA approval of Opsumit (macitentan) for the treatment of pulmonary arterial hypertension . Processed and transmitted by Thomson Reuters ONE.The issuer is solely responsible for the content of this announcement.

Cornerstone Therapeutics Announces Events to Be Held at the 2013 North American Cystic Fibrosis Conference
Cornerstone Therapeutics Inc. (NASDAQ: CRTX) will exhibit at the North American Cystic Fibrosis Conference (NACFC), Oct. 17-19 at the Salt Palace Convention Center in Salt Lake City. The annual scientific meeting, sponsored by the Cystic Fibrosis Foundation, is designed for medical professionals focused on CF research and patient care.

Actelion closes acquisition of privately-held Ceptaris Therapeutics adding Valchlor to Actelion's product portfolio
Actelion Pharmaceuticals Ltd /Actelion closes acquisition of privately-held Ceptaris Therapeutics adding Valchlor to Actelion's product portfolio . Processed and transmitted by Thomson Reuters ONE.The issuer is solely responsible for the content of this announcement.

Onyx Pharmaceuticals Announces Data Presentations at 2013 European Cancer Congress
Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX) today announced the upcoming presentations of data highlighting Nexavar® (sorafenib) tablets and Stivarga® (regorafenib) tablets at the 2013 European Cancer Congress (ECCO/ESMO/ESTRO), September 28 - October 1, 2013 in Amsterdam, Netherlands.

Theravance Announces Reintroduction of VIBATIV(R) (telavancin) to the U.S. Market
Theravance, Inc. (NASDAQ: THRX) announced today that it has commenced shipments of VIBATIV® (telavancin) into the U.S. wholesaler channel. VIBATIV® is approved in the U.S

Cornerstone Therapeutics Initiates PERTZYE(R) (pancrelipase) Sales and Marketing Efforts for the Treatment of Exocrine Pancreatic Insufficiency in Patients With Cystic Fibrosis
Cornerstone Therapeutics Inc. (NASDAQ: CRTX) announced today it is now actively marketing PERTZYE® (pancrelipase) in the U.S. for the treatment of Exocrine Pancreatic Insufficiency (EPI) due to cystic fibrosis. PERTZYE is the only U.S. Food and Drug Administration (FDA) approved pancreatic enzyme replacement therapy (PERT) containing bicarbonate-buffered, enteric-coated microspheres

Theravance Reports Second Quarter 2013 Financial Results
Theravance, Inc. (NASDAQ: THRX) (the "Company") reported today its financial results for the quarter ended June 30, 2013. Revenue for the second quarter of 2013 was $1.3 million. Net loss for the second quarter of 2013 was $36.4 million or $0.37 per diluted share. Cash and cash equivalents, short-term investments and marketable securities totaled $533.3 million as of June 30, 2013.

First Ever Baby Born Through Genetic Derived Human Embryos
Reprogenetics, one of the largest providers of preimplantation genetic diagnosis (PGD) services announced today that one of their researchers Dr

Horizon Pharma to Receive Approval of DUEXIS(R) From the United Kingdom (UK) Medicines and Healthcare Products Regulatory Agency (MHRA)
Horizon Pharma, Inc. (NASDAQ: HZNP) today announced that the United Kingdom (UK) Medicines and Healthcare products Regulatory Agency (MHRA), based on the favorable recommendation of their Commission on Human Medicines (CHM), will grant a Marketing Authorization (MA) for DUEXIS® (ibuprofen/famotidine), pending review of updated licensing documents which the Company has provided to the MHRA

Theravance Reports Favorable Outcome of FDA Advisory Committee Meeting on VIBATIV(R) (telavancin) for the Treatment of Nosocomial Pneumonia
Theravance, Inc. (NASDAQ: THRX) today announced a favorable outcome of the Anti-Infective Drugs Advisory Committee (AIDAC) of the U.S. Food and Drug Administration (FDA) meeting on VIBATIV® (telavancin) for the treatment of nosocomial pneumonia (NP) due to susceptible isolates of Gram-positive microorganisms.

Theravance Announces Posting of Briefing Documents for FDA Anti-Infective Drugs Advisory Committee Meeting on VIBATIV(R) (telavancin)
Theravance, Inc. (NASDAQ: THRX) today announced that the US Food and Drug Administration (FDA) has posted on its website briefing documents for the November 29, 2012 Anti-Infective Drugs Advisory Committee (AIDAC) meeting

Predicting the Future of IVF Using Past Performance as a Model
In a new paper, published in Reproductive Biomedicine Online, Dr. Jacques Cohen of Althea and colleagues propose a projected timeline for achieving the ultimate goal of in vitro fertilization (IVF) techniques: 100% success rate following transfer of a single embryo

Cornerstone Therapeutics Acquires Exclusive U.S. Rights to Chiesi Farmaceutici S.p.A.'s BETHKIS(R) (Tobramycin Inhalation Solution)
Cornerstone Therapeutics Inc. (NASDAQ: CRTX), a specialty pharmaceutical company focused on commercializing products for the hospital and related specialty markets, today announced it has entered into an agreement with Chiesi Farmaceutici S.p.A. (Chiesi) to acquire the U.S

Warner Bros. Records Suggests These Special Items for Upcoming Holiday Gift Guides
It's August and, generally the only people thinking about the holidays are retailers and your annoying friends who get all their holiday shopping done early. But you folks in the media are probably thinking about them too, because your boss has just reminded you that it's Holiday Gift Guide Time! Allow us to help make your lives just a little bit easier

ABRAXANE® Demonstrates Statistically Significant Improvement in Overall Survival for Patients with Advanced Pancreatic Cancer in Phase III Study

ABRAXANE® Demonstrates Significant Improvement in Progression-Free Survival Compared to Standard Chemotherapy in Advanced Melanoma Patients
Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ: CELG) today announced that abstracts for the upcoming Society for Melanoma Research meeting have been published online in the organization’s official journal at http://onlinelibrary.wiley.com/doi/10.1111/pcmr.12023/abstract

ABRAXANE Meets Primary Endpoint of Progression-Free Survival in Phase III Chemotherapy-Naïve Metastatic Melanoma Study
Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ: CELG) has announced results of its phase III, randomized, international study (CA033) of ABRAXANE® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in chemotherapy-naïve patients with metastatic melanoma

Chinese officials apologize to woman for forced abortion under one-child policy
Officials in China have apologized to a woman for forcing her to have an abortion and have suspended three people responsible for the act.

Kids conceived via fertility drugs 'shorter'
Children who are born full term, but are conceived with the help of fertility drugs are slightly shorter than naturally conceived children, a new study has suggested.

Exposure to plastic chemical in womb may cause uterine cancer in offspring
Prenatal exposure to bisphenol A, or BPA, a chemical found in many common plastic household items, can cause numerous genes in the uterus to respond differently to estrogen in adulthood, a study in mouse model has found.

'World first' tumour operation in womb saves foetus
Surgeons were able to successfully remove a tumour from the mouth of a foetus, in what has been described as a "world first" procedure.

Blood test for pregnant women may predict risk of having dangerously small babies
Researchers have found a protein in the blood of pregnant women that can predict if they are likely to have a fetus that doesn't grow properly, and thus has a high risk of stillbirth and long-term health complications.

Genetic screening of unborn babies 'may not be 100 pc accurate'
New tests for genetic screening of unborn babies will not be 100 per cent accurate and may scare parents into believing their children will be born with a disability when they are healthy, a scientist has warned.

Mystery about why fetus isn't rejected as foreign tissue during pregnancy partially solved
Researchers have come closer to answering the long-standing question of why a mother's immune system does not reject a developing fetus as foreign tissue.

Stress during pregnancy can negatively affect newborns' health
Expectant mothers who dealt with the strain of a hurricane or major tropical storm passing nearby during their pregnancy had children who were at elevated risk for abnormal health conditions at birth, a new study has found.

Standing for long during pregnancy may curtail foetal growth
Standing for long durations during pregnancy may curb the growth of the developing foetus, a new study has revealed.

Drinking during pregnancy not safe, experts warn
Experts from U.S have refuted claims that consumption of up to 8 alcoholic drinks a week or occasional binge drinking during pregnancy is generally safe for the developing baby.

Mumbai Police recover foetus from garbage dump
Mumbai Police have recovered a foetus from a garbage dump.

How pregnancy changes 'mommy brain'
Reproductive hormones may prepare a woman's brain for the demands of motherhood-helping her becomes less worked up by stress and more in tune to her baby's needs, a new study has revealed.

Stop signal for common form of skin cancer discovered
An international team of scientists has discovered a gene that helps protect the body from a common form of skin cancer - squamous cell cancer (SCC).

Fetuses sense moms' psychological state through placentas
The fetus growing inside the mother's womb not only hears her heartbeat or the music she might play to her belly, but also gets signals about her mental state through the placenta, which effects the baby's development after birth, a new study has found.

High BP in early pregnancy ups risk of birth defects in offspring
A new study has found that women with high blood pressure (hypertension) in early stages of pregnancy are more likely to have babies with birth defects, irrespective of commonly prescribed medicines for their condition.

Now, iris scan help predict race, gender
A new system has been developed that can pick out similarities between irises instead of the differences, which helps in determining the racial backgrounds and gender of a person.

Placenta-uterus battle could help explain deadly pregnancy disease
Yale scientists have suggested that a battle that brews in the mother's womb between the father's biological goal to produce the biggest, healthiest baby possible against the mother's need to live through delivery might help explain preeclampsia, an often deadly disease of pregnancy.

Horizon Pharma Announces Launch of DUEXIS(R) (Ibuprofen/Famotidine) 800 mg/26.6 mg in the United States
Horizon Pharma, Inc. (NASDAQ: HZNP) today announced that DUEXIS® (ibuprofen/famotidine), a proprietary single-tablet combination of ibuprofen (800 mg) and famotidine (26.6 mg), is now available to U.S

Horizon Pharma and Sanofi Announce FDA Approval of DUEXIS(R) Commercial Manufacturing Facility
Horizon Pharma, Inc. (NASDAQ: HZNP) and Sanofi announced today that the U.S. Food and Drug Administration (FDA) has approved the use of the sanofi-aventis Canada Inc. manufacturing site in Laval, Quebec to manufacture DUEXIS®, (ibuprofen/famotidine) a proprietary single-tablet combination of ibuprofen (800 mg) and famotidine (26.6 mg). DUEXIS was approved by the FDA in April 2011

Pregnancy slows down speed of soon-to-be dolphin mothers
Like for any pregnant mom, even the bottlenose dolphins are subjected to tough and awkward situations during later stages of pregnancy as their speed gets slowed down due to baby bump, a new study has revealed.

Foetal stem cells could be key in healing mother's injured heart
Foetal stem cells help mothers to recuperate from heart damage, a new study by Indian origin scientist has suggested.

Comment on this story

Share